Oncology is one of the most exciting areas in healthcare, as novel therapies continue to emerge that move forward our molecular understanding of the disease and offer effective treatment advances. This Q&A explores oncology innovation with Kantar’s Stephanie Hawthorne, Vice President of Oncology and Specialty Therapeutics.

Merck & Co. Inc. is buying ArQule Inc. for $2.7 billion, seeking to tap into the drug developer’s experimental blood cancer therapy that targets genetic mutations.

Swiss drugmaker Roche released on Monday what it called encouraging early data on cancer drug atezolizumab in combination therapy for treating a form of advanced melanoma.   A phase Ib study of atezolizumab (MPDL3280A), used in combination with the BRAF inhibitor Zelboraf for previously untreated BRAFV600 mutation-positive inoperable or metastatic melanoma, showed adverse events were […]